TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Decline of serum HBV-DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total MRI infarct zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum-tolerated dose (MTD) of vorinostat
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Change From Baseline in Actigraphy-Measured Sleep Latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Performance diagnosis accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area-under-the-ROC-curve (AUC) for classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Mean Number of Infiltrating Absolute CD3+ T Cells/μm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving a Two-fold Increase CD3+ T Cells/μm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Insomnia Severity Index Scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in sleep efficiency (SE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total sleep time (TST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of confirmed PTLD
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of confirmed CNS PTLD
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of PML
Endpoint domain: Adverse events/effects
Primary endpoint: Anastomotic Leak
Endpoint domain: Adverse events/effects
Primary endpoint: Collection
Endpoint domain: Adverse events/effects
Primary endpoint: Peak increase in SCr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of contrast media-induced nephropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Time of application
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diaphragm dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in early literacy skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in prosocial skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in emotion and behavior regulation skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in parenting behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Visual analogue pain score (VAS) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in depression score on HDRS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean SBP Changes (mm Hg) at Visit 3 vs. Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: % of Patients Achieving Target BP Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: # of Angina Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Office Diastolic BP Levels Changes (mm Hg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 28-day Liver-transplantation Free Mortality
Endpoint domain: Mortality/survival
Primary endpoint: 28-day Liver Transplantation Rate
Endpoint domain: Mortality/survival
Primary endpoint: Identification of TAB3 transcript/protein as a molecular marker of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ability to ambulate post operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year progression free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Vital Sign Abnormalities Reported as AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Neurological Abnormalities Reported as AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Total Steps Recorded
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriate antibiotic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: MAC hour consumption of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAC hour consumption of desflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbon footprint of sevoflurane and desflurane
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Predictive value of early serum trough concentrations of ixekizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive value of early anti-drug antibodies of ixekizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of a therapeutic window of ixekizumab in psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Qualitative perceptions surrounding self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Qualitative perceptions surrounding gender
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Surveys with 100% Completion of All Questions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: infection postoperative
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Beck Scale for Suicide Ideation (BSS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number and type of adverse drug events
Endpoint domain: Adverse events/effects
Primary endpoint: Uptake of bevacizumab-IRDye800CW in breast cancer tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serious Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent Stroke or Myocardial Infarction
Endpoint domain: Mortality/survival
Primary endpoint: MS colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain assessed by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Procedural Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of mGluR network mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety Endpoints of SAD
Endpoint domain: Adverse events/effects
Primary endpoint: Safety Endpoints of MAD
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum observed plasma concentration (Cmax) of levoketoconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum concentration (Tmax) of levoketoconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of levoketoconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial or complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of delay under 30 minutes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Psychoneurologic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 4 week continuous quit rate (CQR)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Nurse Delirium Screening Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of Procalcitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of oxygen use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 90-day Major Post-Operative Complication Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Proximal deep vein thrombosis or pulmonary embolism
Endpoint domain: Mortality/survival
Primary endpoint: Difference in actuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Treatment of ROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Facial Wrinkling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-prandial satiety gut hormone area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean Change in Percent Predicted FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of 4.8 g/day 5-ASA
Endpoint domain: Adverse events/effects
Primary endpoint: overall rate of major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective Patient's perception of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Revisions
Endpoint domain: Adverse events/effects
Primary endpoint: Event related potentials (ERPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MTAT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year disease-free survival (DFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Grade > 2 late pelvic toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Annualized New Heterotopic Ossification (HO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of admission for heart failure worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vital signs (blood pressure, heart rate, body temperature)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Unified Dyskinesia Rating Scale (UDysRS) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Immediate social-economic impact of orthopedics trauma
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Quantification of liver steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change from baseline in body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of HLH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urine Stress Marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of complications at the site of spinal fusion
Endpoint domain: Adverse events/effects
Primary endpoint: Healing Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Fasting Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in total lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: quantity of urine leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep characteristics
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Fractional synthetic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Invasive disease free survival (iDFS)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of pulmonary toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of major congenital malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who enroll and complete the serial measures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tumor mutational burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gene expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antigenic landscape and TCR repertoire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total number of neutrophils in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total volume of axillary/breast drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Completing Continuous Four-week Abstinence From Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Experiencing Grade 3 and Grade 4 Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cognitive Ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in patients' GI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in lab data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrencephalographic patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Uterine Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local cutaneous control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety of systemic administration
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mean C-Reactive Protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects who experienced at least 1 treatment-emergent adverse event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects who experienced at least one treatment emergent serious AE (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects who experienced a treatment-emergent dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in nutritional status by Mid-Arm Muscle Circumference (MAMC) evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in nutritional status by Subjective Global Assessment (SGA) evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cerebral Blood Flow of the Orbito-Frontal Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Score Changes in Neurotoxicity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete or partial response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of compound event
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of right sided polyp detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Aura occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Option B+ ARV drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hCG positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Dyspnea severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recommended Phase II dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: DNA Hypomethylation and Re-expression of Silenced Tumor Suppressor Genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decline in ovarian reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Safety of Exenatide infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Verbal Memory Score Change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Visual Memory Score Change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Processing Speed/Attention Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Working Memory Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Reaction Time
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: One-year Overall Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Podocyte structural and functional assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Accuracy of Fluoroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival in months
Endpoint domain: Mortality/survival
Primary endpoint: Total UPDRS I, II, III Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of satiety level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of hunger level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean clinical status score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering of IOP fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Changes in Liebowitz Social Anxiety Scale (LSAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Reported 7-Day Point-Prevalence Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Experience Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Life Space Assessment Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of participants with EPD1503 related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Absence rate of IFDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Absolute bioavailability of mannitol powder for inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability of mannitol powder for inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of mannitol after inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time to Pulpal Response After Mandibular Molar Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time to Pulpal Response After Mandibular Canine Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pigmentation of burn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lateral spread of burn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Regression of new vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinical Composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with Residual Cancer Burden (RCB) 0-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of participants responding positively to treatment question
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative rate of major adverse cardiovascular events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distant angle of deviation after surgical correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limitation of adduction and abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients in Overall Response Categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-measles Virus Antibody Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-mumps Virus Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-rubella Virus Antibody Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone Marrow Colony-Forming Cell Mitomycin-C resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sham credibility rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of any adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Peripheral blood parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Muscle Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fascicle Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pennation Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes